Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

François Ghiringhelli, Cédric Menard, Pierre E. Puig et al. · Cancer Immunology Immunotherapy · 2006 · 1.2K citations · Full text

Life Sciences, Immunology, Oncology +17

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

Douglas J. Schwartzentruber, David H. Lawson, Jon Richards et al. · New England Journal of Medicine · 2011 · 888 citations

Medicine, Immunology, Oncology +14

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

Marco Colleoni, Andrea Rocca, Maria Teresa Sandri et al. · Annals of Oncology · 2002 · 502 citations · Full text

Medicine, Oncology, Pharmacology +17

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

Guido Bocci, Giulio Francia, Shan Man et al. · Proceedings of the National Academy of Sciences · 2003 · 416 citations · Full text

Medicine, Oncology, Pharmacology +17

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects

Marco Colleoni, Laura Orlando, Giuseppina Sanna et al. · Annals of Oncology · 2005 · 188 citations · Full text

Medicine, Oncology, Pharmacology +16